Lung cancer patients now have another treatment option. For those tumors carrying HER2 mutations, can now be treated with trastuzumab deruxtecan. This drug is already approved for use in HER2-positive breast cancer and gastric cancer. Now, it has been approved by the US Food and Drug Administration (FDA) for use in HER2-positive lung cancer. This